Revelation Biosciences Inc (REVB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Revelation Biosciences Inc (REVB) has a cash flow conversion efficiency ratio of -0.254x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.56 Million) by net assets ($10.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Revelation Biosciences Inc market cap and net worth for the company's overall valuation and market capitalisation.
Revelation Biosciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Revelation Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Revelation Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Revelation Biosciences Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Revelation Biosciences Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Techfast Holdings Bhd
KLSE:0084
|
0.129x |
|
Basin Energy Ltd
AU:BSN
|
-0.041x |
|
Cash.Medien AG
HM:MF8
|
N/A |
|
YouGov plc
LSE:YOU
|
0.045x |
|
Soligenix Inc.
NASDAQ:SNGX
|
-0.386x |
|
GreenPower Motor Company Inc
NASDAQ:GP
|
-0.021x |
|
Essentra PLC
LSE:ESNT
|
0.024x |
|
E-Home Household Service Holdings Ltd
NASDAQ:EJH
|
0.004x |
Annual Cash Flow Conversion Efficiency for Revelation Biosciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Revelation Biosciences Inc from 2016 to 2025. View REVB stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.86 Million | $-8.27 Million | -0.933x | +76.02% |
| 2024-12-31 | $4.71 Million | $-18.32 Million | -3.891x | -255.02% |
| 2023-12-31 | $6.65 Million | $-7.29 Million | -1.096x | +89.72% |
| 2022-12-31 | $1.05 Million | $-11.22 Million | -10.660x | -109.56% |
| 2021-12-31 | $-99.47K | $-11.09 Million | 111.497x | +3515821.17% |
| 2020-12-31 | $67.82 Million | $-215.07K | -0.003x | +100.00% |
| 2019-12-31 | $-3.64K | $41.09 Million | -11293.568x | -9182593.30% |
| 2018-12-31 | $264.89 Million | $32.58 Million | 0.123x | -4.50% |
| 2017-12-31 | $188.28 Million | $24.25 Million | 0.129x | +87.38% |
| 2016-12-31 | $168.76 Million | $11.60 Million | 0.069x | -- |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregul… Read more